pharmaceutical company MaaT Pharma secures €37.5 million loan from the European Investment Bank to further develop cancer treatments
MaaT Pharma, a clinical-stage biotechnology company, is making significant strides in the development of microbiome-based therapies for cancer patients. Two of its programs, Xervyteg (formerly MaaT013) and MaaT033, are currently in advanced clinical development stages.
Xervyteg, a potential treatment for acute Graft-versus-Host Disease (aGvHD) after allogeneic stem cell transplant, has shown promising results. The company completed patient recruitment for its pivotal Phase 3 ARES trial in October 2024, with positive topline results announced in January 2025. Following this, MaaT Pharma submitted a marketing authorization application to the European Medicines Agency (EMA) in June 2025, and the product is now under EMA review. MaaT Pharma also signed a commercial distribution agreement with Clinigen for Europe in July 2025, preparing for potential market launch.
Meanwhile, MaaT033, the company's second lead candidate, is undergoing evaluation in a Phase 2b randomized controlled trial to improve survival in patients receiving allogeneic stem cell transplants.
To support these developments, MaaT Pharma secured a €37.5 million structured loan from the European Investment Bank (EIB) in July 2025. This funding aims to advance the clinical development and EMA regulatory processes for both Xervyteg and MaaT033, reflecting strong institutional confidence in the company's innovative microbiome therapies in oncology.
The loan will support MaaT Pharma's late-stage hemato-oncology programs, as the company intends to fund its plans and development programs while preserving shareholder value. This strategic financial move is part of a mix of non-dilutive and dilutive sources, with the partnership financing with Clinigen and debt financing with the EIB being benchmarks reflecting MaaT Pharma's financial strategy.
In addition, Eric Soyer, Chief Financial Officer of MaaT Pharma, expressed gratitude for the EIB's support, stating that the EIB financing represents another step in reinforcing the company's financial position.
With each operational and financing step, MaaT Pharma strengthens its track record, bringing it one step closer to potentially bringing a first microbiome-based therapy to market in Europe.
[1] MaaT Pharma Secures €37.5 Million Loan from European Investment Bank (EIB) [2] MaaT Pharma Announces Positive Topline Results from Phase 3 ARES Trial of Xervyteg for the Treatment of Acute Graft-versus-Host Disease (aGvHD) [3] MaaT Pharma Announces Completion of Patient Enrollment for the ARES Trial of Xervyteg in October 2024 [4] MaaT Pharma and Clinigen Enter into Exclusive Distribution Agreement for Europe [5] MaaT Pharma Submits Marketing Authorization Application to the EMA for Xervyteg in June 2025
The loan of €37.5 million from the European Investment Bank (EIB) is supporting MaaT Pharma's late-stage hemato-oncology programs, which include the development and regulatory processes for microbiome-based therapies like Xervyteg and MaaT033. In a positive development, MaaT Pharma announced positive topline results from the Phase 3 ARES trial of Xervyteg for the treatment of acute Graft-versus-Host Disease (aGvHD), a medical-condition common in cancer patients undergoing health-and-wellness procedures like stem cell transplants.
